Hims and Hers Health Inc vs Starbucks Corp — how do they compare? Hims and Hers Health Inc trades at $30.24 (market cap $7.12B), while Starbucks Corp trades at $107.93 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 17.1× Hims and Hers Health Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | SBUX | |
|---|---|---|
Market Cap | $7.12B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $108.37 |
52-Week Low | $14.52 | $78.46 |
Enterprise Value | $7.82B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.
The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.
Starbucks (SBUX) trades at $107.57, up 2.79% today, showing strong momentum near its 52-week high. The stock benefits from a bullish technical outlook and improved quarterly earnings, with Q2 2026 EPS beating estimates at $0.85 vs. $0.66 expected. Revenue trends are positive, with 2025 revenue reaching $37.18B, though net income margin declined to 5.17%. Recent news highlights a turnaround in traffic and margin expansion, supported by new product launches like carbonated refreshers and seasonal offerings.
The outlook for SBUX is cautiously optimistic, with analyst consensus pointing to a $113.60 price target. Key opportunities include sustained traffic recovery and cost efficiency gains, but risks remain from high valuation (P/E 61.65) and competitive pressures. Investors should weigh the earnings rebound against premium multiples and monitor execution of growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →